Primary Cutaneous Peripheral T-Cell Lymphoma NOS: Diagnostic Criteria and Challenges.
Robson A, Bakr F, Cabeçadas J.
Am J Dermatopathol. 2024 Jul 1;46(7):399-409. doi: 10.1097/DAD.0000000000002547. Epub 2023 Dec 13.
Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C.
J Am Acad Dermatol. 2014 Feb;70(2):205.e1-16; quiz 221-2. doi: 10.1016/j.jaad.2013.07.049.
Primary cutaneous peripheral T-cell lymphomas with a T-follicular helper phenotype: an integrative clinical, pathological and molecular case series study.
Wang L, Rocas D, Dalle S, Sako N, Pelletier L, Martin N, Dupuy A, Tazi N, Balme B, Vergier B, Beylot-Barry M, Carlotti A, Bagot M, Battistella M, Chaby G, Ingen-Housz-Oro S, Gaulard P, Ortonne N.
Br J Dermatol. 2022 Dec;187(6):970-980. doi: 10.1111/bjd.21791. Epub 2022 Sep 2.
Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sezary syndrome. Part I: Clinical and histologic features and diagnosis.
Stoll JR, Willner J, Oh Y, Pulitzer M, Moskowitz A, Horwitz S, Myskowski P, Noor SJ.
J Am Acad Dermatol. 2021 Nov;85(5):1073-1090. doi: 10.1016/j.jaad.2021.04.080. Epub 2021 Apr 30.
Peripheral T-Cell Lymphoma.
Rangoonwala HI, Cascella M.
2023 Aug 7. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.
Horwitz SM, Scarisbrick JJ, Dummer R, Whittaker S, Duvic M, Kim YH, Quaglino P, Zinzani PL, Bechter O, Eradat H, Pinter-Brown L, Akilov OE, Geskin L, Sanches JA, Ortiz-Romero PL, Weichenthal M, Fisher DC, Walewski J, Trotman J, Taylor K, Dalle S, Stadler R, Lisano J, Bunn V, Little M, Prince HM.
Blood Adv. 2021 Dec 14;5(23):5098-5106. doi: 10.1182/bloodadvances.2021004710.
Primary cutaneous peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) simulating periorbital cellulitis.
de Matos PR, Amoedo P, Nogueira A, Lisboa C, Carvalhais I, Fonseca E, Azevedo F.
Int J Dermatol. 2023 Mar;62(3):e125-e128. doi: 10.1111/ijd.16479. Epub 2022 Nov 3.
Primary Cutaneous T-Cell Lymphoblastic Lymphoma: Case Report and Literature Review.
Khurana S, Beltran M, Jiang L, Ayala E, Roy V.
Case Rep Hematol. 2019 Feb 20;2019:3540487. doi: 10.1155/2019/3540487. eCollection 2019.
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.
Prince HM, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL, Akilov OE, Geskin L, Trotman J, Taylor K, Dalle S, Weichenthal M, Walewski J, Fisher D, Dréno B, Stadler R, Feldman T, Kuzel TM, Wang Y, Palanca-Wessels MC, Zagadailov E, Trepicchio WL, Zhang W, Lin HM, Liu Y, Huebner D, Little M, Whittaker S, Duvic M; ALCANZA study group.
Lancet. 2017 Aug 5;390(10094):555-566. doi: 10.1016/S0140-6736(17)31266-7. Epub 2017 Jun 7.
Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach.
Hue SS, Oon ML, Wang S, Tan SY, Ng SB.
Pathology. 2020 Jan;52(1):111-127. doi: 10.1016/j.pathol.2019.09.011. Epub 2019 Nov 22.
